Cleared Special

K072062 - UCP MULTIPLE DRUG SCREEN TEST CUPS

K072062 is the FDA 510(k) clearance for UCP MULTIPLE DRUG SCREEN TEST CUPS by Ucp Biosciences, Inc.. It is a Class 2 Toxicology device (product code LFG) cleared through the Special 510(k) pathway after a 55-day FDA review.

K072062 · Ucp Biosciences, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2007
Decision
55d
Days
Class 2
Risk

K072062 is an FDA 510(k) clearance for the UCP MULTIPLE DRUG SCREEN TEST CUPS. Classified as Radioimmunoassay, Tricyclic Antidepressant Drugs (product code LFG), Class II - Special Controls.

Submitted by Ucp Biosciences, Inc. (San Jose, US). The FDA issued a Cleared decision on September 20, 2007 after a review of 55 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3910 - the FDA toxicology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Ucp Biosciences, Inc. devices

Submission Details

510(k) Number K072062 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 27, 2007
Decision Date September 20, 2007
Days to Decision 55 days
Submission Type Special
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
32d faster than avg
Panel avg: 87d · This submission: 55d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code LFG Radioimmunoassay, Tricyclic Antidepressant Drugs
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3910
Definition Intended To Measure Any Of The Tricyclic Antidepressant Drugs In Serum Or Urine.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - LFG Radioimmunoassay, Tricyclic Antidepressant Drugs

All 16
Devices cleared under the same product code (LFG) and FDA review panel - the closest regulatory comparables to K072062.
Healgen Propoxyphene Test (Strip, Cassette, Cup, Dip Card), Healgen Nortriptyline Test (Strip, Cassette, Cup, Dip Card), Healgen EDDP (Methadone Metabolite) Test (Strip, Cassette, Cup, Dip Card)
K151348 · Healgen Scientific, LLC · Aug 2015
CR3 Keyless Split Sample Cup Nortriptyline-Buprenorphine
K142609 · Guangzhou Wondfo Biotech Co., Ltd. · Dec 2014
WONDFO PHENCYCLIDINE URINE TEST, TRICYCLIC ANTIDEPRESSANTS URINE TEST
K112395 · Guangzhou Wondfo Biotech Co., Ltd. · Sep 2011
ACON TCA ONE STEP TRICYCLIC ANTIDEPRESSANT TEST STRIP AND DEVICE
K021526 · ACON Laboratories, Inc. · Jul 2002
ACCUSIGN TCA, BIOSIGN TCA, STAUS DS TCA
K980249 · Princeton BioMeditech Corp. · Mar 1998
EMIT NORTRIPTYLINE ASSAY
K870823 · Syva Co. · Mar 1987